Clinical Trial

Pilot Study Evaluating Tumor Microenvironment Interaction in Solid Tumor Patients

Withdrawn Early Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
No patients enrolled onto study. Administratively withdrawn.
Summary
This pilot study aims to compare PET/CT imaging using 68Ga-FAPI-46 to imaging results from standard MRI or CT with contrast in patients with solid tumors undergoing biologic therapy. A total of 50 participants will receive an intravenous injection of 68Ga-FAPI-46 and undergo a PET/CT scan shortly after received the study drug. Imaging will occur before starting standard antibody-based therapy. Participants will then proceed with their treatment, and the study team will monitor them through chart reviews for up to 36 months to evaluate treatment response and any correlation with tumor uptake observed on PET/CT scans.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-03; most recent amendment 2026-01-18.
Status change: Not Yet Recruiting → Withdrawn 2026-01-18
Trial Details
NCT Number NCT06922825
Lead Sponsor Eben Rosenthal
Collaborators: Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center
Conditions Solid Tumor Cancer, Solid Tumor Malignancy, Cancer, Malignancy
Start Date 2027-01
Primary Completion 2032-04 (estimated)
Study Completion 2032-09 (estimated)
Updated on ClinicalTrials.gov 2026-01-21